Search

Your search keyword '"Pawarode, Attaphol"' showing total 91 results
Start Over Author "Pawarode, Attaphol" Search Limiters Academic (Peer-Reviewed) Journals
91 results on '"Pawarode, Attaphol"'

2. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

Author

Jain, Tania, Estrada-Merly, Noel, Salas, M. Queralt, Kim, Soyoung, DeVos, Jakob, Chen, Min, Fang, Xi, Kumar, Rajat, Andrade-Campos, Marcio, Elmariah, Hany, Agrawal, Vaibhav, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Ballen, Karen, Beitinjaneh, Amer, Bhatt, Vijaya Raj, Bredeson, Christopher, DeFilipp, Zachariah, Dholaria, Bhagirathbhai, Farhadfar, Nosha, Farhan, Shatha, Gandhi, Arpita P., Ganguly, Siddhartha, Gergis, Usama, Grunwald, Michael R., Hamad, Nada, Hamilton, Betty K., Inamoto, Yoshihiro, Iqbal, Madiha, Jamy, Omer, Juckett, Mark, Kharfan-Dabaja, Mohamed A., Krem, Maxwell M., Lad, Deepesh P., Liesveld, Jane, Al Malki, Monzr M., Malone, Adriana K., Murthy, Hemant S., Ortí, Guillermo, Patel, Sagar S., Pawarode, Attaphol, Perales, Miguel-Angel, van der Poel, Marjolein, Ringden, Olle, Rizzieri, David A., Rovó, Alicia, Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Ustun, Celalettin, Verdonck, Leo F., Wingard, John R., Wirk, Baldeep, Bejanyan, Nelli, Jones, Richard J., Nishihori, Taiga, Oran, Betul, Nakamura, Ryotaro, Scott, Bart, Saber, Wael, and Gupta, Vikas

Published
2024
Full Text
View/download PDF

3. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

Author

Etra, Aaron, El Jurdi, Najla, Katsivelos, Nikolaos, Kwon, Deukwoo, Gergoudis, Stephanie, Morales, George, Spyrou, Nikolaos, Kowalyk, Steven, Aguayo-Hiraldo, Paibel, Akahoshi, Yu, Ayuk, Francis, Baez, Janna, Betts, Brian C., Chanswangphuwana, Chantiya, Chen, Yi-Bin, Choe, Hannah, DeFilipp, Zachariah, Gleich, Sigrun, Hexner, Elizabeth, Hogan, William J., Holler, Ernst, Kitko, Carrie L., Kraus, Sabrina, Al Malki, Monzr, MacMillan, Margaret, Pawarode, Attaphol, Quagliarella, Francesco, Qayed, Muna, Reshef, Ran, Schechter, Tal, Vasova, Ingrid, Weisdorf, Daniel, Wölfl, Matthias, Young, Rachel, Nakamura, Ryotaro, Ferrara, James L. M., Levine, John E., and Holtan, Shernan

Published
2024
Full Text
View/download PDF

4. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients

Author

Boyiadzis, Michael, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Battiwalla, Minoo, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Castillo, Paul, Cerny, Jan, Copelan, Edward A., Craddock, Charles, Dholaria, Bhagirathbhai, Perez, Miguel Angel Diaz, Ebens, Christen L., Gale, Robert Peter, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Iqbal, Madiha, Jamy, Omer, Kharfan-Dabaja, Mohamed A., Khera, Nandita, Lazarus, Hillard M., Lin, Richard, Modi, Dipenkumar, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar S., Pawarode, Attaphol, Saber, Wael, Sharma, Akshay, Solh, Melhem, Wagner, John L., Wang, Trent, Williams, Kirsten M., Winestone, Lena E., Wirk, Baldeep, Zeidan, Amer, Hourigan, Christopher S., Litzow, Mark, Kebriaei, Partow, de Lima, Marcos, Page, Kristin, and Weisdorf, Daniel J.

Published
2023
Full Text
View/download PDF

5. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

Author

Magenau, John, Jaglowski, Samantha, Uberti, Joseph, Farag, Sherif S., Riwes, Mary Mansour, Pawarode, Attaphol, Anand, Sarah, Ghosh, Monalisa, Maciejewski, John, Braun, Thomas, Devenport, Martin, Lu, Susan, Banerjee, Bhramori, DaSilva, Carolyn, Devine, Steven, Zhang, Mei-Jie, Burns, Linda J., Liu, Yang, Zheng, Pan, and Reddy, Pavan

Published
2024
Full Text
View/download PDF

6. Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors

Author

Vasbinder, Alexi, Hoeger, Christopher W., Catalan, Tonimarie, Anderson, Elizabeth, Chu, Catherine, Kotzin, Megan, Xie, Jeffrey, Kaakati, Rayan, Berlin, Hanna P., Shadid, Husam, Perry, Daniel, Pan, Michael, Takiar, Radhika, Padalia, Kishan, Mills, Jamie, Meloche, Chelsea, Bardwell, Alina, Rochlen, Matthew, Blakely, Pennelope, Leja, Monika, Banerjee, Mousumi, Riwes, Mary, Magenau, John, Anand, Sarah, Ghosh, Monalisa, Pawarode, Attaphol, Yanik, Gregory, Nathan, Sunita, Maciejewski, John, Okwuosa, Tochukwu, and Hayek, Salim S.

Published
2023
Full Text
View/download PDF

7. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

Author

Tamari, Roni, McLornan, Donal P., Ahn, Kwang Woo, Estrada-Merly, Noel, Hernández-Boluda, Juan Carlos, Giralt, Sergio, Palmer, Jeanne, Gale, Robert Peter, DeFilipp, Zachariah, Marks, David I., van der Poel, Marjolein, Verdonck, Leo F., Battiwalla, Minoo, Diaz, Miguel Angel, Gupta, Vikas, Ali, Haris, Litzow, Mark Robert, Lazarus, Hillard M., Gergis, Usama, Bashey, Asad, Liesveld, Jane, Hashmi, Shahrukh, Pu, Jeffrey J., Beitinjaneh, Amer, Bredeson, Christopher, Rizzieri, David, Savani, Bipin N., Abid, Muhammad Bilal, Ganguly, Siddhartha, Agrawal, Vaibhav, Ulrike Bacher, Vera, Wirk, Baldeep, Jain, Tania, Cutler, Corey, Aljurf, Mahmoud, Kindwall-Keller, Tamila, Kharfan-Dabaja, Mohamed A., Hildebrandt, Gerhard C., Pawarode, Attaphol, Solh, Melhem M., Yared, Jean A., Grunwald, Michael R., Nathan, Sunita, Nishihori, Taiga, Seo, Sachiko, Scott, Bart L., Nakamura, Ryotaro, Oran, Betul, Czerw, Tomasz, Yakoub-Agha, Ibrahim, and Saber, Wael

Published
2023
Full Text
View/download PDF

8. Impact of second primary malignancy postautologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Author

Ragon, Brittany Knick, Shah, Mithun Vinod, D’Souza, Anita, Estrada-Merly, Noel, Gowda, Lohith, George, Gemlyn, de Lima, Marcos, Hashmi, Shahrukh, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Banerjee, Rahul, Saad, Ayman, Hildebrandt, Gerhard C., Mian, Hira, Abid, Muhammad Bilal, Battiwalla, Minoo, Lekakis, Lazaros J., Patel, Sagar S., Murthy, Hemant S., Nieto, Yago, Strouse, Christopher, Badawy, Sherif M., Al Hadidi, Samer, Dholaria, Bhagirathbhai, Aljurf, Mahmoud, Vesole, David H., Lee, Cindy H., Pawarode, Attaphol, Gergis, Usama, Miller, Kevin C., Holmberg, Leona A., Afrough, Aimaz, Solh, Melhem, Munshi, Pashna N., Nishihori, Taiga, Anderson, Larry D., Jr., Wirk, Baldeep, Kaur, Gurbakhash, Qazilbash, Muzaffar H., Shah, Nina, Kumar, Shaji K., and Usmani, Saad Z.

Published
2023
Full Text
View/download PDF

9. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification

Author

Etra, Aaron, Gergoudis, Stephanie, Morales, George, Spyrou, Nikolaos, Shah, Jay, Kowalyk, Steven, Ayuk, Francis, Baez, Janna, Chanswangphuwana, Chantiya, Chen, Yi-Bin, Choe, Hannah, DeFilipp, Zachariah, Gandhi, Isha, Hexner, Elizabeth, Hogan, William J., Holler, Ernst, Kapoor, Urvi, Kitko, Carrie L., Kraus, Sabrina, Lin, Jung-Yi, Al Malki, Monzr, Merli, Pietro, Pawarode, Attaphol, Pulsipher, Michael A., Qayed, Muna, Reshef, Ran, Rösler, Wolf, Schechter, Tal, Van Hyfte, Grace, Weber, Daniela, Wölfl, Matthias, Young, Rachel, Özbek, Umut, Ferrara, James L.M., and Levine, John E.

Published
2022
Full Text
View/download PDF

11. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

Author

Nazha, Aziz, Hu, Zhen-Huan, Wang, Tao, Lindsley, R. Coleman, Abdel-Azim, Hisham, Aljurf, Mahmoud, Bacher, Ulrike, Bashey, Asad, Cahn, Jean-Yves, Cerny, Jan, Copelan, Edward, DeFilipp, Zachariah, Diaz, Miguel Angel, Farhadfar, Nosha, Gadalla, Shahinaz M., Gale, Robert Peter, George, Biju, Gergis, Usama, Grunwald, Michael R., Hamilton, Betty, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Kalaycio, Matt, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Majhail, Navneet S., Murthy, Hemant S., Nathan, Sunita, Nishihori, Taiga, Pawarode, Attaphol, Rizzieri, David, Sabloff, Mitchell, Savani, Bipin N., Schachter, Levanto, Schouten, Harry C., Seo, Sachiko, Shah, Nirav N., Solh, Melhem, Valcárcel, David, Vij, Ravi, Warlick, Erica, Wirk, Baldeep, Wood, William A., Yared, Jean A., Alyea, Edwin, Popat, Uday, Sobecks, Ronald M., Scott, Bart L., Nakamura, Ryotaro, and Saber, Wael

Published
2020
Full Text
View/download PDF

12. Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin's lymphoma.

Author

Frame, David G., Geer, Marcus, Kasha, Salena, Markstrom, Denise, Scappaticci, Gianni, Feeney, Tate, Hayduk, Andrew, Mansoor, Hilary M., Oberfeld, Avery, D'Antonio, Hannah, Anand, Sarah, Sung Won Choi, Maciejewski, John, Pawarode, Attaphol, Riwes, Mary Mansour, Tewari, Muneesh, Magenau, John, and Ghosh, Monalisa

Subjects
NON-Hodgkin's lymphoma, T cells, CD19 antigen, CYTOKINE release syndrome, ELECTRONIC health records
Abstract

Introduction: Lymphodepleting chemotherapy (LDC) is critical to CAR T-cell expansion and efficacy. Despite this, there is not a consensus in the literature regarding the optimal LDC regimen, including dose and frequency. Methods: We retrospectively reviewed consecutive patients at a single institution that received LDC prior to treatment with the CD19 directed CAR T-cell products axicabtagene ciloleucel and tisagenlecleucel. Patients treated at our center received fludarabine 30 mg/m2 and cyclophosphamide 500 mg/m2 for 3 consecutive days prior to May 2019. After this timepoint patients routinely received fludarabine 40 mg/m² and cyclophosphamide 500 mg/m² for 2 consecutive days. Clinical data from each cohort were obtained from the electronic medical record and compared for differences in CAR T-cell efficacy and toxicity. Results: From June 2018 to August 2023, LDC was given to 92 patients prior to CD19 directed CAR T-cell therapy for relapsed non-Hodgkin's lymphoma. Twenty-eight patients received a 3-day regimen, and 64 patients received a 2-day regimen. In the total cohort, 75% of patients received axicabtagene ciloleucel and 25% received tisagenlecleucel. The overall response rates in both the 2-day regimen group and the 3-day regimen group were similar (69% vs 75%, p= 0.21) as were the complete response rates (50% vs 54%, p=0.82). There were no significant differences between the 2-day and 3-day regimens for grade 2-4 cytokine release syndrome (55% vs 50%, p=0.82), grade 2-4 immune effector cell associated-neurotoxicity syndrome (42% vs 29%, p=0.25), or time to resolution of neutropenia or thrombocytopenia. The rate of prolonged platelet recovery lasting greater than 60 days was higher with the 3-day regimen (9% vs 27%, p=0.026). Discussion: As the number of patients eligible for CAR T-cell therapy continues to increase, optimizing each component of therapy is necessary. We show that a 2-day regimen of LDC with fludarabine and cyclophosphamide is feasible without significant impact on CAR T-cell efficacy or toxicity. Prospective studies are necessary to further determine the most effective LDC regimen. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

Author

Zhou, Zheng, Nath, Rajneesh, Cerny, Jan, Wang, Hai-Lin, Zhang, Mei-Jie, Abdel-Azim, Hisham, Agrawal, Vaibhav, Ahmed, Gulrayz, Al-Homsi, A. Samer, Aljurf, Mahmoud, Alkhateeb, Hassan B., Assal, Amer, Bacher, Ulrike, Bajel, Ashish, Bashir, Qaiser, Battiwalla, Minocher, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Choe, Hannah, Copelan, Edward, Cutler, Corey, Damlaj, Moussab B., DeFilipp, Zachariah, De Lima, Marcos, Diaz, Miguel Angel, Farhadfar, Nosha, Foran, James, Freytes, César O., Gerds, Aaron T., Gergis, Usama, Grunwald, Michael R., Gul, Zartash, Hamadani, Mehdi, Hashmi, Shahrukh, Hertzberg, Mark, Hildebrandt, Gerhard C., Hossain, Nasheed, Inamoto, Yoshihiro, Isola, Luis, Jain, Tania, Kamble, Rammurti T., Khan, Muhammad Waqas, Kharfan-Dabaja, Mohamed A., Kebriaei, Partow, Kekre, Natasha, Khera, Nandita, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark, Liu, Hongtao, Marks, David I., Martino, Rodrigo, Mathews, Vikram, Mishra, Asmita, Murthy, Hemant S., Nagler, Arnon, Nakamura, Ryotaro, Nathan, Sunita, Nishihori, Taiga, Olin, Rebecca, Olsson, Richard F., Palmisiano, Neil, Patel, Sagar S., Patnaik, Mrinal M., Pawarode, Attaphol, Perales, Miguel-Angel, Politikos, Ioannis, Popat, Uday, Rizzieri, David, Sandmaier, Brenda M., Savani, Bipin N., Seo, Sachiko, Shah, Nirav N., Uy, Geoffrey L., Valcárcel, David, Verdonck, Leo F., Waller, Edmund K., Wang, Youjin, Weisdorf, Daniel, Wirk, Baldeep, Wong, Eric, Yared, Jean A., and Saber, Wael

Published
2020
Full Text
View/download PDF

14. Survival following allogeneic transplant in patients with myelofibrosis

Author

Gowin, Krisstina, Ballen, Karen, Ahn, Kwang Woo, Hu, Zhen-Huan, Ali, Haris, Arcasoy, Murat O., Devlin, Rebecca, Coakley, Maria, Gerds, Aaron T., Green, Michael, Gupta, Vikas, Hobbs, Gabriela, Jain, Tania, Kandarpa, Malathi, Komrokji, Rami, Kuykendall, Andrew T., Luber, Kierstin, Masarova, Lucia, Michaelis, Laura C., Patches, Sarah, Pariser, Ashley C., Rampal, Raajit, Stein, Brady, Talpaz, Moshe, Verstovsek, Srdan, Wadleigh, Martha, Agrawal, Vaibhav, Aljurf, Mahmoud, Angel Diaz, Miguel, Avalos, Belinda R., Bacher, Ulrike, Bashey, Asad, Beitinjaneh, Amer M., Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Cutler, Corey S., DeFilipp, Zachariah, Gadalla, Shahinaz M., Ganguly, Siddhartha, Grunwald, Michael R., Hashmi, Shahrukh K., Kharfan-Dabaja, Mohamed A., Kindwall-Keller, Tamila, Kröger, Nicolaus, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Marks, David I., Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Pawarode, Attaphol, Rowe, Jacob M., Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Tamari, Roni, Verdonck, Leo F., Yared, Jean A., Alyea, Edwin, Popat, Uday, Sobecks, Ronald, Scott, Bart L., Nakamura, Ryotaro, Mesa, Ruben, and Saber, Wael

Published
2020
Full Text
View/download PDF

15. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

Author

Dhakal, Binod, Patel, Sagar, Girnius, Saulius, Bachegowda, Lohith, Fraser, Raphael, Davila, Omar, Kanate, Abraham S., Assal, Amer, Hanbali, Amr, Bashey, Asad, Pawarode, Attaphol, Freytes, César O., Lee, Cindy, Vesole, David, Cornell, Robert Frank, Hildebrandt, Gerhard C., Murthy, Hemant S., Lazarus, Hillard M., Cerny, Jan, Yared, Jean A., Schriber, Jeffrey, Berdeja, Jesus, Stockerl-Goldstein, Keith, Meehan, Kenneth, Holmberg, Leona, Solh, Melhem, Diaz, Miguel Angel, Kharfan-Dabaja, Mohamed A., Farhadfar, Nosha, Bashir, Qaiser, Munker, Reinhold, Olsson, Richard F., Gale, Robert P., Bayer, Ruthlee-Lu, Seo, Sachiko, Chhabra, Saurabh, Hashmi, Shahrukh, Badawy, Sherif M., Nishihori, Taiga, Gonsalves, Wilson, Nieto, Yago, Efebera, Yvonne, Kumar, Shaji, Shah, Nina, Qazilbash, Muzaffar, Hari, Parameswaran, and D’Souza, Anita

Published
2020
Full Text
View/download PDF

19. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research

Author

Murthy, Hemant S., Ahn, Kwang Woo, Estrada-Merly, Noel, Alkhateeb, Hassan B., Bal, Susan, Kharfan-Dabaja, Mohamed A., Dholaria, Bhagirathbhai, Foss, Francine, Gowda, Lohith, Jagadeesh, Deepa, Sauter, Craig, Abid, Muhammad Bilal, Aljurf, Mahmoud, Awan, Farrukh T., Bacher, Ulrike, Badawy, Sherif M., Battiwalla, Minoo, Bredeson, Chris, Cerny, Jan, Chhabra, Saurabh, Deol, Abhinav, Diaz, Miguel Angel, Farhadfar, Nosha, Freytes, César, Gajewski, James, Gandhi, Manish J., Ganguly, Siddhartha, Grunwald, Michael R., Halter, Joerg, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Jimenez-Jimenez, Antonio Martin, Kalaycio, Matt, Kamble, Rammurti, Krem, Maxwell M., Lazarus, Hillard M., Lazaryan, Aleksandr, Maakaron, Joseph, Munshi, Pashna N., Munker, Reinhold, Nazha, Aziz, Nishihori, Taiga, Oluwole, Olalekan O., Ortí, Guillermo, Pan, Dorothy C., Patel, Sagar S., Pawarode, Attaphol, Rizzieri, David, Saba, Nakhle S., Savani, Bipin, Seo, Sachiko, Ustun, Celalettin, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Wirk, Baldeep, Oran, Betul, Nakamura, Ryotaro, Scott, Bart, and Saber, Wael

Published
2022
Full Text
View/download PDF

20. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD

Author

Major-Monfried, Hannah, Renteria, Anne S., Pawarode, Attaphol, Reddy, Pavan, Ayuk, Francis, Holler, Ernst, Efebera, Yvonne A., Hogan, William J., Wölfl, Matthias, Qayed, Muna, Hexner, Elizabeth O., Wudhikarn, Kitsada, Ordemann, Rainer, Young, Rachel, Shah, Jay, Hartwell, Matthew J., Chaudhry, Mohammed S., Aziz, Mina, Etra, Aaron, Yanik, Gregory A., Kröger, Nicolaus, Weber, Daniela, Chen, Yi-Bin, Nakamura, Ryotaro, Rösler, Wolf, Kitko, Carrie L., Harris, Andrew C., Pulsipher, Michael, Reshef, Ran, Kowalyk, Steven, Morales, George, Torres, Ivan, Özbek, Umut, Ferrara, James L.M., and Levine, John E.

Published
2018
Full Text
View/download PDF

21. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia

Author

Hogan, William, Battiwalla, Minoo, Copelan, Edward, Hildebrandt, Gerhard, Ganguly, Sid, Majhail, Navneet, Woolfrey, Ann, Nivison-Smith, Ian, Hertzberg, Mark, Diaz, Miguel Angel, Jakubowski, Ann, Ustun, Celalettin, Yong, Agnes, Freytes, Cesar, DeFilipp, Zachariah, Inamoto, Yoshi, Cahn, Jean-Yves, Savani, Bipin, Yared, Jean, Bajel, Ashish, Bacher, Ulrike, Uy, Geoffrey, Rizzieri, David, Wieduwilt, Matthew, Schultz, Kirk, Grunwald, Michael, Kamble, Rammurti, Qayed, Muna, Brammer, Jonathan, Ballen, Karen, Khera, Nandita, Schouten, Harry, Bierings, Marc, Kanakry, Christopher, Wood, William Allen, Saad, Ayman, Savoie, Lynn, Hamilton, Betty Ky, Aljurf, Mahmoud, Vij, Ravi, Pawarode, Attaphol, Olsson, Richard, Wirk, B. Mona, Beitinjaneh, Amer, Seo, Sachiko, Cerny, Jan, Akpek, Gorgun, Norkin, Maxim, Nishihori, Taiga, Lazaryan, Aleksandr, Sabloff, Mitchell, Kebriaei, Partow, Anasetti, Claudio, Zhang, Mei-Jie, Wang, Hai-Lin, Aldoss, Ibrahim, de Lima, Marcos, Khoury, H. Jean, Sandmaier, Brenda M., Horowitz, Mary M., Artz, Andrew, Bejanyan, Nelli, Ciurea, Stefan, Lazarus, Hillard M., Gale, Robert Peter, Litzow, Mark, Bredeson, Christopher, Seftel, Matthew D., Pulsipher, Michael A., Boelens, Jaap-Jan, Alvarnas, Joseph, Champlin, Richard, Forman, Stephen, Pullarkat, Vinod, Weisdorf, Daniel, and Marks, David I.

Published
2018
Full Text
View/download PDF

24. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Author

Muffly, Lori, Pasquini, Marcelo C., Martens, Michael, Brazauskas, Ruta, Zhu, Xiaochun, Adekola, Kehinde, Aljurf, Mahmoud, Ballen, Karen K., Bajel, Ashish, Baron, Frederic, Battiwalla, Minoo, Beitinjaneh, Amer, Cahn, Jean-Yves, Carabasi, Mathew, Chen, Yi-Bin, Chhabra, Saurabh, Ciurea, Stefan, Copelan, Edward, D'Souza, Anita, Edwards, John, Foran, James, Freytes, Cesar O., Fung, Henry C., Gale, Robert Peter, Giralt, Sergio, Hashmi, Shahrukh K., Hildebrandt, Gerhard C., Ho, Vincent, Jakubowski, Ann, Lazarus, Hillard, Luskin, Marlise R., Martino, Rodrigo, Maziarz, Richard, McCarthy, Philip, Nishihori, Taiga, Olin, Rebecca, Olsson, Richard F., Pawarode, Attaphol, Peres, Edward, Rezvani, Andrew R., Rizzieri, David, Savani, Bipin N., Schouten, Harry C., Sabloff, Mitchell, Seftel, Matthew, Seo, Sachiko, Sorror, Mohamed L., Szer, Jeff, Wirk, Baldeep M., Wood, William A., and Artz, Andrew

Published
2017
Full Text
View/download PDF

26. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes

Author

Oran, Betül, Ahn, Kwang Woo, Fretham, Caitrin, Beitinjaneh, Amer, Bashey, Asad, Pawarode, Attaphol, Wirk, Baldeep, Scott, Bart L., Savani, Bipin N., Bredeson, Christopher, Weisdorf, Daniel, Marks, David I., Rizzieri, David, Copelan, Edward, Hildebrandt, Gerhard C., Hale, Gregory A., Murthy, Hemant S., Lazarus, Hillard M., Cerny, Jan, Liesveld, Jane L., Yared, Jean A., Yves-Cahn, Jean, Szer, Jeffrey, Verdonck, Leo F., Aljurf, Mahmoud, van der Poel, Marjolein, Litzow, Mark, Kalaycio, Matt, Grunwald, Michael R., Diaz, Miguel Angel, Sabloff, Mitchell, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Farhadfar, Nosha, Reshef, Ran, Olsson, Richard F., Gale, Robert Peter, Nakamura, Ryotaro, Seo, Sachiko, Chhabra, Saurabh, Hashmi, Shahrukh, Farhan, Shatha, Ganguly, Siddhartha, Nathan, Sunita, Nishihori, Taiga, Jain, Tania, Agrawal, Vaibhav, Bacher, Ulrike, Popat, Uday, and Saber, Wael

Published
2021
Full Text
View/download PDF

28. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

Author

Epperla, Narendranath, Ahn, Kwang W., Litovich, Carlos, Ahmed, Sairah, Battiwalla, Minoo, Cohen, Jonathon B., Dahi, Parastoo, Farhadfar, Nosha, Farooq, Umar, Freytes, Cesar O., Ghosh, Nilanjan, Haverkos, Bradley, Herrera, Alex, Hertzberg, Mark, Hildebrandt, Gerhard, Inwards, David, Kharfan-Dabaja, Mohamed A., Khimani, Farhad, Lazarus, Hillard, Lazaryan, Aleksandr, Lekakis, Lazaros, Murthy, Hemant, Nathan, Sunita, Nishihori, Taiga, Pawarode, Attaphol, Prestidge, Tim, Ramakrishnan, Praveen, Rezvani, Andrew R., Romee, Rizwan, Shah, Nirav N., Sureda, Ana, Fenske, Timothy S., and Hamadani, Mehdi

Published
2019
Full Text
View/download PDF

29. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study

Author

Bejanyan, Nelli, Zhang, Meijie, Bo-Subait, Khalid, Brunstein, Claudio, Wang, Hailin, Warlick, Erica D., Giralt, Sergio, Nishihori, Taiga, Martino, Rodrigo, Passweg, Jakob, Dias, Ajoy, Copelan, Edward, Hale, Gregory, Gale, Robert Peter, Solh, Melhem, Kharfan-Dabaja, Mohamed A., Diaz, Miguel Angel, Ganguly, Siddhartha, Gore, Steven, Verdonck, Leo F., Hossain, Nasheed M., Kekre, Natasha, Savani, Bipin, Byrne, Michael, Kanakry, Christopher, Cairo, Mitchell S., Ciurea, Stefan, Schouten, Harry C., Bredeson, Christopher, Munker, Reinhold, Lazarus, Hillard, Cahn, Jean-Yves, van Der Poel, Marjolein, Rizzieri, David, Yared, Jean A., Freytes, Cesar, Cerny, Jan, Aljurf, Mahmoud, Palmisiano, Neil D., Pawarode, Attaphol, Bacher, Vera Ulrike, Grunwald, Michael R., Nathan, Sunita, Wirk, Baldeep, Hildebrandt, Gerhard C., Seo, Sachiko, Olsson, Richard F., George, Biju, de Lima, Marcos, Hourigan, Christopher S., Sandmaier, Brenda M., Litzow, Mark, Kebriaei, Partow, Saber, Wael, and Weisdorf, Daniel

Published
2021
Full Text
View/download PDF

31. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies

Author

Pasquini, Marcelo C., Zhang, Mei-Jie, Medeiros, Bruno C., Armand, Philippe, Hu, Zhen-Huan, Nishihori, Taiga, Aljurf, Mahmoud D., Akpek, Görgün, Cahn, Jean-Yves, Cairo, Mitchell S., Cerny, Jan, Copelan, Edward A., Deol, Abhinav, Freytes, César O., Gale, Robert Peter, Ganguly, Siddhartha, George, Biju, Gupta, Vikas, Hale, Gregory A., Kamble, Rammurti T., Klumpp, Thomas R., Lazarus, Hillard M., Luger, Selina M., Liesveld, Jane L., Litzow, Mark R., Marks, David I., Martino, Rodrigo, Norkin, Maxim, Olsson, Richard F., Oran, Betul, Pawarode, Attaphol, Pulsipher, Michael A., Ramanathan, Muthalagu, Reshef, Ran, Saad, Ayman A., Saber, Wael, Savani, Bipin N., Schouten, Harry C., Ringdén, Olle, Tallman, Martin S., Uy, Geoffrey L., Wood, William A., Jr., Wirk, Baldeep, Pérez, Waleska S., Batiwalla, Minoo, and Weisdorf, Daniel J.

Published
2016
Full Text
View/download PDF

32. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series

Author

Pawarode, Attaphol, Mineishi, Shin, Reddy, Pavan, Braun, Thomas M., Khaled, Yasser A., Choi, Sung W., Magenau, John M., Harris, Andrew C., Connelly, James A., Kitko, Carrie L., Parkin, Brian L., Goldstein, Steven C., Yanik, Gregory A., Levine, John E., Ferrara, James L., and Couriel, Daniel R.

Published
2016
Full Text
View/download PDF

33. Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Author

Gatza, Erin, Braun, Thomas, Levine, John E., Ferrara, James L.M., Zhao, Shuang, Wang, Tianyi, Chang, Lawrence, Harris, Andrew, Pawarode, Attaphol, Kitko, Carrie, Magenau, John M., Yanik, Gregory A., Couriel, Daniel R., Goldstein, Steven, Connelly, James, Reddy, Pavan, Paczesny, Sophie, and Choi, Sung Won

Published
2014
Full Text
View/download PDF

34. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial

Author

Choi, Sung Won, Braun, Thomas, Chang, Lawrence, Ferrara, James L M, Pawarode, Attaphol, Magenau, John M, Hou, Guoqing, Beumer, Jan H, Levine, John E, Goldstein, Steve, Couriel, Daniel R, Stockerl-Goldstein, Keith, Krijanovski, Oleg I, Kitko, Carrie, Yanik, Gregory A, Lehmann, Michael H, Tawara, Isao, Sun, Yaping, Paczesny, Sophie, Mapara, Markus Y, Dinarello, Charles A, DiPersio, John F, and Reddy, Pavan

Published
2014
Full Text
View/download PDF

36. Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission

Author

Magenau, John M., Braun, Thomas, Reddy, Pavan, Parkin, Brian, Pawarode, Attaphol, Mineishi, Shin, Choi, Sung, Levine, John, Li, Yumeng, Yanik, Gregory, Kitko, Carrie, Churay, Tracey, Frame, David, Riwes, Mary Mansour, Harris, Andrew, Bixby, Dale, Couriel, Daniel R., and Goldstein, Steven C.

Published
2015
Full Text
View/download PDF

42. The utility of cognitive changes in identifying those with acute graft vs. host disease following allogeneic hematopoietic cell transplant.

Author

Stratton, John, Sylvia, Allison, Hoodin, Flora, Choi, Sung Won, Pawarode, Attaphol, Giordani, Bruno, and Votruba, Kristen

Subjects
GRAFT versus host disease, TOTAL body irradiation, HLA histocompatibility antigens, TRANSPLANTATION of organs, tissues, etc., SHORT-term memory
Abstract

Objectives: Acute graft versus host disease (aGVHD) is a common complication of allogeneic hematopoietic cell transplant (HCT) and is associated with morbidity and mortality. Identifying those at risk for developing aGVHD is crucial for early intervention. The current study assessed whether scores on a brief cognitive screening measure could identify those that develop aGVHD by 100 days post-HCT. Methods: Participants were 37 patients undergoing allogeneic HCT, assessed prior to transplant, and at 30- and 100-days post-HCT. Of those completing all evaluations, patients were divided into those who did (n = 14) and did not (n = 16) develop aGVHD by day 100 post-HCT. At 100 days post-transplant, groups did not differ on relevant demographic factors, disease, conditioning regimen, relatedness of donor, stem cell source, steroid use, total body irradiation use, human leukocyte antigens (HLA) match, or frequency of infection. Results: At 100 days post-HCT, those with aGVHD performed significantly worse on a working memory measure than those without aGvHD. The presence of aGVHD at day 100 increased significantly with every one standard deviation decrease in working memory from baseline to 30 days post-HCT (odds ratio = 3.08; 95% CI: 1.00–9.36). These findings were observed despite a small sample size and statistically controlling for multiple analyses. Conclusions: While this study is exploratory in nature, and has a small sample size, findings suggest that early detection of working memory declines could coincide with, or signal the development of, aGVHD. Potential etiologies are discussed. Implementing early cognitive screening within the first 30 days post-HCT may be useful in identifying patients at risk for aGVHD. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

43. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T‐cell lymphoma, nasal type: a CIBMTR analysis.

Author

Kanate, Abraham S., DiGilio, Alyssa, Ahn, Kwang W., Al Malki, Monzr, Jacobsen, Eric, Steinberg, Amir, Hamerschlak, Nelson, Kharfan‐Dabaja, Mohamed, Salit, Rachel, Ball, Edward, Bashir, Qaiser, Cashen, Amanda, Couriel, Daniel, Diez‐Martin, Jose, Katsanis, Emmanuel, Linhares, Yulia, Mori, Shahram, Nash, Richard, Pawarode, Attaphol, and Perales, Miguel‐Angel

Subjects
HEMATOPOIETIC stem cell transplantation, GRAFT versus host disease, KILLER cells, T-cell lymphoma, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISOLONE
Abstract

The article focuses on allogeneic haematopoietic cell transplantation for extranodal natural killer and T-cell lymphoma and association with Epstein–Barr virus (EBV). It mentions treatment with cyclophosphamide, doxorubicin and prednisolone like therapies alone generally does not provide durable remissions and reduced-intensity (RIC) or myeloablative conditioning (MAC). It also mentions relapse remains a major cause of treatment-failure.

Published
2018
Full Text
View/download PDF

44. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.

Author

Schriber, Jeffrey R., Hari, Parameswaran N., Ahn, Kwang Woo, Fei, Mingwei, Costa, Luciano J., Kharfan‐Dabaja, Mohamad A., Angel‐Diaz, Miguel, Gale, Robert P., Ganguly, Siddharatha, Girnius, Saulius K., Hashmi, Shahrukh, Pawarode, Attaphol, Vesole, David H., Wiernik, Peter H., Wirk, Baldeep M., Marks, David I., Nishihori, Taiga, Olsson, Richard F., Usmani, Saad Z., and Mark, Tomer M.

Subjects
HEALTH of Hispanic Americans, HEMATOPOIETIC stem cell transplantation, MULTIPLE myeloma treatment, EPIDEMIOLOGY, DISEASE incidence, STATISTICS on Black people, STATISTICS on Hispanic Americans, AUTOGRAFTS, ETHNIC groups, HEALTH services accessibility, HEALTH status indicators, MULTIPLE myeloma, RESEARCH funding, TUMOR classification, WHITE people, ACQUISITION of data, KARNOFSKY Performance Status, IMPACT of Event Scale
Abstract

Background: Race/ethnicity remains an important barrier in clinical care. The authors investigated differences in the receipt of autologous hematopoietic cell transplantation (AHCT) among patients with multiple myeloma (MM) and outcomes based on race/ethnicity in the United States.Methods: The Center for International Blood and Marrow Transplant Research database was used to identify 28,450 patients who underwent AHCT for MM from 2008 through 2014. By using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results 18 registries, the incidence of MM was calculated, and a stem cell transplantation utilization rate (STUR) was derived. Post-AHCT outcomes were analyzed among patients ages 18 to 75 years who underwent melphalan-conditioned peripheral cell grafts (N = 24,102).Results: The STUR increased across all groups from 2008 to 2014. The increase was substantially lower among Hispanics (range, 8.6%-16.9%) and non-Hispanic blacks (range, 12.2%-20.5%) compared with non-Hispanic whites (range, 22.6%-37.8%). There were 18,046 non-Hispanic whites, 4123 non-Hispanic blacks, and 1933 Hispanic patients. The Hispanic group was younger (P < .001). Fewer patients older than 60 years underwent transplantation among Hispanics (39%) and non-Hispanic blacks (42%) compared with non-Hispanic whites (56%). A Karnofsky score <90% and a hematopoietic cell transplantation comorbidity index score >3 were more common in non-Hispanic blacks compared with Hispanic and non-Hispanic whites (P < .001). More Hispanics (57%) versus non-Hispanic blacks (54%) and non-Hispanic whites (52%; P < .001) had stage III disease. More Hispanics (48%) versus non-Hispanic blacks (45%) and non-Hispanic whites (44%) had a very good partial response or better before transplantation (P = .005). Race/ethnicity did not impact post-AHCT outcomes.Conclusions: Although the STUR increased, it remained low and was significantly lower among Hispanics followed by non-Hispanic blacks compared with non-Hispanic whites. Race/ethnicity did not impact transplantation outcomes. Efforts to increase the rates of transplantation for eligible patients who have MM, with an emphasis on groups that underuse transplantation, are warranted. Cancer 2017;123:3141-9. © 2017 American Cancer Society. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

46. Isochromosome 1q in a myelodysplastic syndrome after treatment for acute promyelocytic leukemia

Author

Pawarode, Attaphol, Finlay, Esme, Sait, Sheila N.J., Barcos, Maurice, and Baer, Maria R.

Subjects
*MYELOID leukemia, *DYSPLASIA, *OLDER men, *CANCER
Abstract

Abstract: A growing body of literature reports therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) in patients treated successfully for acute promyelocytic leukemia (APL). We report a t-MDS with an isochromosome 1q as a sole abnormality, 47,XY,+1,i(1)(q10), in a 46-year-old man with APL 14 years after he was treated with cytosine arabinosine and daunorubicin. The literature on t-MDS/t-AML after APL therapy and on isochromosome 1q is reviewed. [Copyright &y& Elsevier]

Published
2006
Full Text
View/download PDF

47. A Phase I/II Clinical Trial of Type 1 Interferon for Reduction of Relapse after HCT in High Risk AML.

Author

Magenau, John M, Pawarode, Attaphol, Riwes, Mary M, Parkin, Brian, Anand, Sarah, Ghosh, Monalisa, Bixby, Dale L, Choi, Sung, Bischoff, Lynne, Yanik, Gregory A., Braun, Thomas, and Reddy, Pavan

Subjects
*HEMATOPOIETIC stem cell transplantation, *ACUTE myeloid leukemia treatment, *CANCER relapse, *GRAFT versus host disease, *CD8 antigen, *CLINICAL trials
Abstract

Introduction Relapse remains a significant challenge towards improving survival after allogeneic hematopoietic transplantation (HCT) for Acute Myeloid Leukemia (AML) not in remission or possessing poor cytogenetic/molecular features. Insights from murine pre-clinical studies demonstrate a central role for CD8+ dendritic cells in cross-presentation of leukemia associated antigens (LAA) in mediating GVL without aggravating acute Graft-versus-Host Disease (aGVHD)(Toubai, Blood 2013). We posited that enhancing LAA cross-presentation with exogenous Type I Interferon (pegIFNα) would promote GVL response and reduce rates of relapse after HCT. Methods We initiated a prospective, phase I/II, clinical trial of pegIFNα administration after myeloablative conditioning for prevention of relapse in pts with detectable AML at time of HCT (resistant to induction) or with cytogenetic/molecular features conferring high relapse risk and poor survival. Pts received up to four doses of 90mcg or 180mcg pegIFNα SubQ on d -1 and d 14, 28, 42 after PBSC or BMT. aGVHD prophy was tacrolimus + MTX or MMF. The primary endpoint was to determine the incidence of relapse in pts receiving the phase II dosage of pegIFNα. We hypothesized that 30 pts assigned to the same dose would provide 80% power to detect a difference between a promising day 180 relapse rate of 40% versus a rate of 60%. Results A total of 30 pts received study treatment at a median age of 60 years (17-72). Conditioning was myeloablative FluBu (n=9), CloBu (n=20) or FluCyTBI (n=1). At time of HCT, AML was detected in 28 pts and 2 pts enrolled for poor cytogenetic/molecular risk, complex/monosomal karyotype (n=1) and FLT3-ITD+ (n=1). There was no DLT at 90mcg (n=3) and one DLT (graft failure) after escalation to 180mcg (n=27). pegIFNα was well tolerated with ≥3 doses administered to 87% of pts. ≥Grade 3 SAEs during treatment include acute kidney injury(n=1), engraftment failure(n=1), bone pain/weakness(n=1), hypotension(n=1) and hypoxemia (n=1). 29 pts (97%) experienced primary engraftment and bone marrow exam at d 30 revealed CR in 100% of pts. Thirteen pts (43%) experienced infection. Grade II-IV aGVHD and grade III-IV aGVHD occurred in 35% (20 – 56%) and 11% (4 – 30%) by day 180. The incidence of TRM was 11% (3-30%) at day 180 and 19% (8-41%) at 1-yr. The day 180 (and 1-yr) incidence of relapse was 39% (24 – 60%) in the overall cohort and 36% (20 – 58%) in 27 pts treated at the phase II dose. At a median follow up of 19 months, the 1-yr OS was 42% (27 – 65%). Conclusion These data provide initial evidence of clinical translation for pegIFNα when administered prophylactically in an AML cohort at high risk for relapse. Type I Interferon did not significantly alter toxicity or aGVHD risk and produced relatively low rates of relapse suggesting a robust GVL response. The role of type 1 IFN in reducing clinical relapse and its underlying biological mechanisms warrants additional study. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

48. Phase 1 Study of Carfilzomib in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies.

Author

Pawarode, Attaphol, Couriel, Daniel R., Braun, Thomas, Magenau, John M., Riwes, Mary M., Parkin, Brian L., Radojcic, Vedran, Frame, David, Choi, Sung Won, Reddy, Pavan, and Goldstein, Steven C.

Subjects
*GRAFT versus host disease, *HEMATOLOGIC malignancies, *HEMATOPOIETIC stem cell transplantation, *PROTEASOME inhibitors, *CD34 antigen, *THERAPEUTICS, *DISEASE risk factors
Published
2016
Full Text
View/download PDF

49. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.

Author

Magenau, John, Tobai, Hiromi, Pawarode, Attaphol, Braun, Thomas, Peres, Edward, Reddy, Pavan, Kitko, Carrie, Sung Choi, Yanik, Gregory, Frame, David, Harris, Andrew, Erba, Harry, Kujawski, Lisa, Elenitoba-Johnson, Kojo, Sanks, Jennifer, Jones, Dawn, Paczesny, Sophie, Ferrara, James, Levine, John, and Mineishi, Shin

Subjects
*ANTINEOPLASTIC agents, *HEMATOPOIETIC stem cells, *STEM cell transplantation, *ACUTE myeloid leukemia, *HYPOXEMIA
Abstract

Patients with hematologic malignancies not in remission before allogeneic hematopoietic stem cell transplantation (HSCT) have a poor prognosis. To improve the antitumor activity of conditioning, we combined clofarabine with myeloablative doses of busulfan in a phase 1/2 study in nonremission hematologic malignancies. Forty-six patients were enrolled, including 31 patients with nonremission acute myelogenous leukemia (AML). Patients had a median age of 53 years, with a median comorbidity index of 3. Donors were unrelated, HLA mismatched, or both in 59% of patients. Common grade III to IV nonhematologic toxicities included transient transaminitis (50%), mucositis (24%), hand-foot syndrome (13%), transient hypoxia (13%), nausea/vomiting (9%), and diarrhea (9%). All patients engrafted. Complete remission was achieved in 80% of all patients by day +30 and in 100% of AML patients without prior hematopoietic stem cell transplantation. Two-year nonrelapse mortality for all patients was 31%, and overall survival was 28%. In AML, the overall survival was 48% at 1 year and 35% at 2 years. These data suggest that clofarabine combined with myeloablative doses of busulfan is well tolerated, secures engraftment, and possesses significant antitumor activity, particularly in nonremission AML. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

50. α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.

Author

Magenau, John M., Goldstein, Steven C., Peltier, Dan, Soiffer, Robert J., Braun, Thomas, Pawarode, Attaphol, Riwes, Mary M., Kennel, Maggi, Antin, Joseph H., Cutler, Corey S., Ho, Vincent T., Alyea III, Edwin P., Parkin, Brian L., Yanik, Gregory A., Sung Won Choi, Lewis, Eli C., Dinarello, Charles A., Koreth, John, and Reddy, Pavan

Subjects
*GRAFT versus host disease, *ADRENOCORTICAL hormones, *IMMUNOSUPPRESSIVE agents, *HEMATOPOIETIC stem cell transplantation, *ALPHA 1-antitrypsin, *STEROIDS, *THERAPEUTICS
Abstract

Corticosteroid resistance after acute graft-versus-host disease (SR-aGVHD) results in high morbidity and mortality after allogeneic hematopoietic cell transplantation. Current immunosuppressive therapies for SR-aGVHD provide marginal effectiveness because of poor response or excessive toxicity, primarily from infection. α1-Antitrypsin (AAT), a naturally abundant serine protease inhibitor, is capable of suppressing experimental GVHD by downmodulating inflammation and increasing ratios of regulatory (Treg) to effector T cells (Teffs). In this prospective multicenter clinical study, we sought to determine the safety and response rate of AAT administration in SR-aGVHD. Forty patients with a median age of 59 years received intravenous AAT twice weekly for 4 weeks as first-line treatment of SR-aGVHD. The primary end point was overall response rate (ORR), the proportion of patients with SR-aGVHD in complete (CR) or partial response by day 28 without addition of further immunosuppression. Treatment was well tolerated without drug-related adverse events. A significant increase in serum levels of AAT was observed after treatment. The ORR and CR rates by day 28 were 65% and 35%, respectively, and included responses in all aGVHD target organs. At day 60, responses were sustained in 73% of patients without intervening immunosuppression. Infectious mortality was 10% at 6 months and 2.5% within 30 days of last AAT infusion. Consistent with preclinical data, correlative samples showed an increase in ratio of activated Tregs to Teffs after AAT treatment. These data suggest that AAT is safe and may be potentially efficacious in treating SR-aGVHD. This trial was registered at www.clinicaltrials.gov as #NCT01700036. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results